How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease

Reviews in Gastroenterological Disorders

Volumn 4, Issue SUPPL. 3, 2004, Pages

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

ABT 874; Adalimumab; CDP870; Crohn's disease; Fontolizumab; Human anti chimeric antibody; Hypersensitivity reactions; Infliximab; Infusion reactions; MRA; Natalizumab; Sargramostim

Indexed keywords

ABT 874; ADALIMUMAB; ADRENALIN; ANTIHISTAMINIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DIPHENHYDRAMINE; FONTOLIZUMAB; GAMMA INTERFERON ANTIBODY; HUMAN MONOCLONAL ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MERCAPTOPURINE; METHYLPREDNISOLONE; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; PARACETAMOL; PLACEBO; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLAXIS; APNEA; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RECEPTOR BINDING; DRUG TARGETING; FEVER; FLUSHING; GENE TARGETING; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFUSION REACTION; LEUKOCYTOSIS; LUPUS ERYTHEMATOSUS; MYALGIA; RASH; SIDE EFFECT; THORAX PAIN; URTICARIA;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CROHN DISEASE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INFUSIONS, INTRAVENOUS; PREDNISONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10044276715     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet. 2002; 359:1541-1549.
2. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease [see comment]. Gastroenterology. 2004;126:402-413.
3. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-508.
5. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
6. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
7. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
8. Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment [abstract]. Gastroenterology. 1999;116:A731.
9. Shen C, Maerten P, Van Assche G, et al. A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocytes and T cells. Gastroenterology. In press.
10. Hanauer S, Lukas M, MacIntosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology. 2004;127:332.
11. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease [abstract]. Gastroenterology. 2004;126:A53-A54.
12. Hanauer S, Present D, Targan SR, et al. CDP571, a humanized monoclonal antibody to TNF-a, is well tolerated in Crohn's disease patients with previous hypersensitivity in infliximab [abstract]. Gastroenterology. 2003;124:A-517.
13. Sandborn WJ, Hanauer SB, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1990.
14. Schreiber S, Rutgeerts P, Fedorak R, et al. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD) [abstract]. Gastroenterology. 2003;124:A-61.
15. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
16. Rutgeerts P, Colombel J, Enns R, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). Gut. 2003;52(suppl VI): A239.
17. Sandborn W, Colombel JF, Enns R, et al. A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). Gastroenterology. 2004;127:332.
18. Feagan BG, Greenberg G, Wild G, et al. Efficacy and safety of a humanized a4β7 antibody in active Crohn's disease (CD) [abstract]. Gastroenterology. 2003;124:A25-A26.
19. Mannon P, Fuss I, Mayer L, et al. Anti-interleukin-12 treats active Crohn's disease [abstract]. Gastroenterology. 2004;126:A22-A23.
20. Hommes D, Mikhajlova T, Stoinov S, et al. Fontolizumab (HuZAF), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology. 2004;127:332.
21. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-996.
22. Berlex Laboratories. Berlex Laboratories announces results from randomized, placebo-controlled study of Leukine(R) for Crohn's disease [press release]. Available at: http://www.berlex.com/html/press/articles/10142003.html. Accessed August 30, 2004.